Anbio Biotechnology (FRA:N3B)

Market Cap	381.64M -76.9%
Revenue (ttm)	7.36M +5.6%
Net Income	5.45M +169.9%
EPS	0.12 +161.3%
Shares Out	n/a
PE Ratio	69.98
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	8.40
Previous Close	7.95
Day's Range	8.25 - 9.00
52-Week Range	7.70 - 43.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Anbio Biotechnology

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2021
• Employees: 27
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: N3B

Financial Performance

In 2025, Anbio Biotechnology's revenue was $8.65 million, an increase of 5.64% compared to the previous year's $8.19 million. Earnings were $6.40 million, an increase of 169.86%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 24, 2026

Data Sources Report a data error